About evotec se - EVO
Evotec SE is a life science company, which engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the Shared R&D and Just–Evotec Biologics segments. The Shared R&D segment includes drug discovery and development services and solutions. The Just–Evotec Biologics segment provides services related to designing, discovering, developing, and manufacturing of modern biotherapeutics. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, Charles Weissmann, and Nobel Laureate on December 8, 1993 and is headquartered in Hamburg, Germany.
EVO At a Glance
Evotec SE
Essener Bogen 7
Hamburg, Hamburg 22419
| Phone | 49-40-560-81-0 | Revenue | 862.07M | |
| Industry | Pharmaceuticals: Major | Net Income | -212,095,760.12 | |
| Sector | Health Technology | 2024 Sales Growth | 2.043% | |
| Fiscal Year-end | 12 / 2025 | Employees | 4,827 | |
| View SEC Filings |
EVO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.711 |
| Price to Book Ratio | 1.496 |
| Price to Cash Flow Ratio | 75.98 |
| Enterprise Value to EBITDA | -20.231 |
| Enterprise Value to Sales | 1.762 |
| Total Debt to Enterprise Value | 0.30 |
EVO Efficiency
| Revenue/Employee | 178,593.71 |
| Income Per Employee | -43,939.457 |
| Receivables Turnover | 3.812 |
| Total Asset Turnover | 0.374 |
EVO Liquidity
| Current Ratio | 1.979 |
| Quick Ratio | 1.889 |
| Cash Ratio | 1.152 |
EVO Profitability
| Gross Margin | 8.264 |
| Operating Margin | -21.461 |
| Pretax Margin | -29.678 |
| Net Margin | -24.603 |
| Return on Assets | -9.207 |
| Return on Equity | -19.078 |
| Return on Total Capital | -14.715 |
| Return on Invested Capital | -13.436 |
EVO Capital Structure
| Total Debt to Total Equity | 46.132 |
| Total Debt to Total Capital | 31.569 |
| Total Debt to Total Assets | 22.008 |
| Long-Term Debt to Equity | 41.232 |
| Long-Term Debt to Total Capital | 28.215 |